Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Müller, E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Müller, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Economic analysis of bleeding and thromboembolic sequelae after heart valve replacement (GELIA 7)

E. Müller* and R. Bergemann GELIA Study Group

Institute for Medical Outcome Research, Lorrach, Germany

* Correspondence: Dr. Elvira Müller, MPH, Institute for Medical Outcome Research, Herrenstr. 4, D-79539 Lörrach, Germany.

Abstract

Aims To conduct an economic analysis of the coagulation-related complications bleeding and thromboembolism following heart valve replacement.

Method and results: Incidences of thromboembolic and bleeding events and subtypes in the German Experience with Low Intensity Anticoagulation (GELIA) study were determined. Based on these data, stroke incidences in a hypothetical cohort of 10,000 patients were calculated over a period of 10 years. Associated lifetime costs were assigned in order to estimate the economic burden of stroke. A cost-effectiveness ratio was estimated for patient self-management of anticoagulation. In the GELIA study severe thromboembolic and bleeding complications occurred at rates of 0·45% and 2·62% per patient-year, respectively. Within the thromboembolic complications stroke was the most common (62%), whereas bleeding events were dominated by gastrointestinal bleeds (38%). For 10,000 patients, costs associated with stroke management amounted to DM26 million for thromboembolic and DM54 million for bleeding events within 10 years. In the GELIA study, patient self-management reduced the incidence of severe complications by 30%. An evaluation of self-management for 5000 patients yielded a cost-effectiveness ratio of DM105,000 per life-year gained.

Conclusion Major differences exist between bleeding and thromboembolic events with respect to incidence, subtype and related costs. Strokes due to bleeding exert a higher economic burden than do thromboembolic strokes. The incidence of lethal strokes may be reduced by patient self-management at an acceptable cost-effectiveness ratio.

Key Words: Bleeding • cost-effectiveness ratio • economical aspects • heart valve replacement • thromboembolism


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.